NO964874L - Fusjonsglykoprotein fra HCMV og HSV - Google Patents

Fusjonsglykoprotein fra HCMV og HSV

Info

Publication number
NO964874L
NO964874L NO964874A NO964874A NO964874L NO 964874 L NO964874 L NO 964874L NO 964874 A NO964874 A NO 964874A NO 964874 A NO964874 A NO 964874A NO 964874 L NO964874 L NO 964874L
Authority
NO
Norway
Prior art keywords
hsv
hcmv
glycoprotein
fusion glycoprotein
virus
Prior art date
Application number
NO964874A
Other languages
English (en)
Other versions
NO964874D0 (no
Inventor
Dirk Richard Gheysen
Original Assignee
Smithkline Beecham Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog
Publication of NO964874L publication Critical patent/NO964874L/no
Publication of NO964874D0 publication Critical patent/NO964874D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/03—Herpetoviridae, e.g. pseudorabies virus
    • C07K14/035—Herpes simplex virus I or II
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Et fusjonsprotein omfattende en del av et glykoprotein HCMV, humant DNA virus tilhørende familien av herpes virus, koblet til en del av et glykoprotein HSV (herpes simplex virus) er beskrevet. Rekombinante proteiner ifølge oppfinnelsen kan anvendes for utvikling av vaksi- ner for å forhindre HCMV infeksjon og/eller HSV infeksjon.
NO964874A 1994-05-18 1996-11-15 Fusjonsglykoprotein fra HCMV og HSV NO964874D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9409962A GB9409962D0 (en) 1994-05-18 1994-05-18 Novel compounds
PCT/EP1995/001800 WO1995031555A1 (en) 1994-05-18 1995-05-11 Fusion glycoprotein from hcmv and hsv

Publications (2)

Publication Number Publication Date
NO964874L true NO964874L (no) 1996-11-15
NO964874D0 NO964874D0 (no) 1996-11-15

Family

ID=10755348

Family Applications (1)

Application Number Title Priority Date Filing Date
NO964874A NO964874D0 (no) 1994-05-18 1996-11-15 Fusjonsglykoprotein fra HCMV og HSV

Country Status (21)

Country Link
US (3) US5889168A (no)
EP (2) EP1529845B1 (no)
JP (1) JPH10500009A (no)
KR (1) KR970703428A (no)
AT (2) ATE483809T1 (no)
AU (1) AU2527195A (no)
BR (1) BR9507728A (no)
CA (1) CA2190529A1 (no)
CY (1) CY2597B2 (no)
DE (2) DE69534162T2 (no)
DK (1) DK0759995T3 (no)
ES (2) ES2239758T3 (no)
GB (1) GB9409962D0 (no)
HK (1) HK1012415A1 (no)
HU (1) HU9603163D0 (no)
NO (1) NO964874D0 (no)
PL (1) PL317235A1 (no)
PT (1) PT759995E (no)
SI (1) SI0759995T1 (no)
WO (1) WO1995031555A1 (no)
ZA (1) ZA953961B (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9409962D0 (en) * 1994-05-18 1994-07-06 Smithkline Beecham Biolog Novel compounds
IL137998A0 (en) * 1998-03-09 2001-10-31 Smithkline Beecham Biolog Combined vaccine compositions
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
WO2006047176A1 (en) * 2004-10-22 2006-05-04 Cargill, Incorporated Process for the production of maltodextrins and maltodextrins
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
CN102333539B (zh) * 2008-12-25 2014-06-25 一般财团法人化学及血清疗法研究所 重组禽传染性鼻炎疫苗及其制备方法
AU2010313339B2 (en) 2009-10-30 2016-05-26 The Administrators Of The Tulane Educational Fund Peptide compositions and methods for inhibiting herpesvirus infection
ES2635014T3 (es) 2010-10-15 2017-10-02 Glaxosmithkline Biologicals S.A. Antígeno gB del citomegalovirus
EP3049092A4 (en) * 2013-09-24 2017-09-06 Duke University Compositions, methods and kits for eliciting an immune response
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
US11857622B2 (en) 2020-06-21 2024-01-02 Pfizer Inc. Human cytomegalovirus GB polypeptide

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171568A (en) * 1984-04-06 1992-12-15 Chiron Corporation Recombinant herpes simplex gb-gd vaccine
CA1337395C (en) * 1986-10-20 1995-10-24 Rae Lyn Burke Recombinant herpes simplex gb-gd vaccine
AU641121B2 (en) * 1988-01-29 1993-09-16 Chiron Corporation Recombinant CMV neutralizing proteins
GB9409962D0 (en) * 1994-05-18 1994-07-06 Smithkline Beecham Biolog Novel compounds

Also Published As

Publication number Publication date
GB9409962D0 (en) 1994-07-06
KR970703428A (ko) 1997-07-03
DE69536112D1 (de) 2010-11-18
ATE483809T1 (de) 2010-10-15
PL317235A1 (en) 1997-03-17
CY2597B2 (en) 2010-03-03
AU2527195A (en) 1995-12-05
ZA953961B (en) 1996-02-26
US5739292A (en) 1998-04-14
HK1012415A1 (en) 1999-07-30
ES2239758T3 (es) 2005-10-01
EP1529845A3 (en) 2006-03-08
US5889168A (en) 1999-03-30
DK0759995T3 (da) 2005-08-01
PT759995E (pt) 2005-07-29
NO964874D0 (no) 1996-11-15
CA2190529A1 (en) 1995-11-23
BR9507728A (pt) 1997-09-23
US6036959A (en) 2000-03-14
DE69534162T2 (de) 2006-03-09
ES2353134T3 (es) 2011-02-25
DE69534162D1 (de) 2005-05-25
SI0759995T1 (en) 2005-10-31
WO1995031555A1 (en) 1995-11-23
EP1529845B1 (en) 2010-10-06
EP0759995B1 (en) 2005-04-20
EP0759995A1 (en) 1997-03-05
HU9603163D0 (en) 1997-01-28
JPH10500009A (ja) 1998-01-06
ATE293697T1 (de) 2005-05-15
EP1529845A2 (en) 2005-05-11

Similar Documents

Publication Publication Date Title
ES8500322A1 (es) Un metodo de modificar un virus para conferirle una nueva funcion biologica.
PT83434B (pt) Processo de preparacao de virus recombinantes, de peptidos ou proteinas e de vacinas contra o sindroma de imunodeficiencia adquirida
ES2061708T3 (es) Virus recombinante de la viruela de la gallina, vectores de expresion de proteinas heterologas y vacunas para aves de corral derivadas de este virus.
NO964874L (no) Fusjonsglykoprotein fra HCMV og HSV
DK0596979T3 (da) Rekombinante nucleinsyrer fra plantevirus
ATE423203T1 (de) Rekombinantes virales vektorsystem
ATE326479T1 (de) Varianten von antigenen des menschlichen papillomvirus
ATE286132T1 (de) Dns-fragmente des gag-gens von lav
HUP9802819A2 (hu) Hősokkfehérje-alapú oltóanyagok és immunterápiák
ATE340859T1 (de) Rekombinantes papillomavirus l1 protein
DE3587991T2 (de) Rekombinanter herpes simplex gb-gd impfstoff.
DE3853139T2 (de) Rekombinanter, fremde gene enthaltender menschlicher cytomegalovirus und seine verwendung.
PT586076E (pt) Vacinas de adenovirus recombinantes
HUP9901005A2 (hu) Herpeszvírusok RFHV/KSHV-alcsaládjába tartozó vírusokból származó glikoprotein-B
ATE189702T1 (de) Das für das pferde herpes-virus typ 1 glykoprotein d, kodierende gen, sein genprodukt, antikörper und ihre verwendung
DE69432730D1 (de) Rekombinante Adenovirus-Vakzinen
ATE109158T1 (de) Rubella-e1 und c peptide.
ES2149822T3 (es) Peptidos inmunorreactivos procedentes del virus de epstein-barr.
DE69010910D1 (de) Polypeptidhemmer für virale replikation.
WO1998023752A3 (de) Papillomviren, mittel zu deren nachweis sowie zur therapie von durch sie verursachten erkrankungen
HUP0103871A2 (hu) Rekombináns CELO-vírus és CELO vírus DNS
AU1948788A (en) Expression of immunologically active proteins of human b-lymphotropic virus
NO942075L (no) Rekombinante virus omfattende kunstig proteolytisk spaltingssete
ES2105984A1 (es) Adenovirus recombinantes que expresan antigenos del virus de la gastroenteritis porcina transmisible (vgpt) y su empleo en la formacion de vacunas.
ATE102252T1 (de) Rekombinantes gefluegelpockenvirus, expressionsvektoren fuer heterologische proteine und davon derivierte gefluegelvakzine.